Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Summers Value Fund Andrew Summers | “We began building a position in Journey Medical in February. Journey is a dermatology-focused pharmaceutical company with products including Accutane for the treatment of acne and Qbrexza for excessive underarm sweating (hyperhidrosis). The company generated $55 million in revenue in 2024, with a modest operating loss. Journey is led by CEO Claude Marauoi, along with several senior members who previously worked at Medicis, a dermatology company acquired by Bausch Health for $2.6 billion in 2012. This group brings deep sector experience and holds a significant equity stake in the business. We were attracted to Journey ahead of the launch of Emrosi, a new oral treatment for rosacea approved by the FDA in November 2024. In Phase 3 trials, Emrosi was tested head-to-head against Oracea, the prior standard of care (with peak sales of over $300 million before going generic) and showed superior efficacy with a similar safety profile. With patent protection through 2039, we believe Emrosi is well positioned to become the new standard of care among oral rosacea therapies. Emrosi launched in April, and early prescription demand has been strong, with sales already annualizing over $15 million. Journey's cost structure — including thirty-five sales reps — is already in place, so revenue growth should scale efficiently. We believe Emrosi could reach $100 million in sales within a few years, making the company profitable and cash flow positive. We forecast untaxed earnings per share of $1.50 by 2027 and assign a price target of $20 per share. BSD Analysis: Journey Medical is a high-stakes, specialized pharma pure-play whose stock is an asymmetric recovery bet on its successful commercialization of niche dermatological drugs. The core thesis is driven by the company's focus on acquiring and developing therapeutics for underserved, chronic skin conditions. This strategy targets markets with high barriers to entry and less generic competition. The stock is a volatile, high-risk play on the successful execution of its commercial strategy, relying on converting new drug approvals and label expansions into accelerated revenue and a definitive path to sustained profitability.” | BULL | Q2 2025 Jul 21, 2025 | View Pitch |
Minot Light Capital Partners Tom Wetherald and Eddie Reilly | “Journey Medical represents a compelling specialty pharmaceutical play backed by its recent FDA approval of Emrosi for treating Rosacea. Emrosi has shown clinical superiority over the current industry standard, Oracea, and can be aggressively marketed using the company's existing salesforce, driving massive high-margin earnings growth starting mid-2025. Given that the current stock price nearly matches the value of its legacy portfolio alone, the market is mispricing this massive launch opportunity.” | BULL | Q4 2024 Jan 1, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
